Financial Performance - Revenue for Q3 2024 reached ¥253,020,064.77, an increase of 20.48% year-over-year[2] - Net profit attributable to shareholders was ¥12,943,174.20, up 48.76% compared to the same period last year[2] - Net profit after deducting non-recurring gains and losses was ¥12,822,455.55, reflecting a 52.13% increase year-over-year[2] - Total operating revenue for Q3 2024 reached ¥635,030,298.87, an increase of 21.3% compared to ¥523,639,966.97 in the same period last year[20] - Operating profit for Q3 2024 was ¥31,450,295.28, down 8.0% from ¥34,527,160.94 in Q3 2023[21] - Net profit attributable to shareholders of the parent company was ¥13,496,659.38, a decrease of 17.4% from ¥16,321,536.90 in the previous year[22] - The company reported a decrease in comprehensive income attributable to shareholders of the parent company to ¥30,221,773.21 from ¥37,234,881.52 in the previous year[22] - Basic earnings per share for Q3 2024 were ¥0.0161, compared to ¥0.0194 in Q3 2023[22] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,565,747,164.97, representing a 1.94% increase from the end of the previous year[2] - The total assets of the company as of the latest report amount to CNY 1,565,747,164.97, an increase from CNY 1,535,890,599.57 at the beginning of the period[18] - The company's current liabilities total CNY 893,347,731.93, slightly up from CNY 891,757,164.96 at the beginning of the period[18] - Total liabilities increased to ¥1,073,322,431.77 from ¥1,070,747,639.58 year-over-year[19] - Shareholders' equity attributable to the parent company increased to ¥447,820,785.37, a rise of 3.47% compared to the end of last year[2] - The company’s total equity increased to ¥492,424,733.20, compared to ¥465,142,959.99 in Q3 2023[19] Cash Flow - Cash flow from operating activities for the year-to-date was ¥43,066,291.87, down 5.89% compared to the previous year[2] - The company reported a net cash flow from operating activities of ¥43,066,291.87, slightly down from ¥45,761,050.12 in Q3 2023[23] - Net cash flow from investment activities was -7,246,655.63, a decrease from 8,465,505.96 in the previous period[24] - Cash inflow from financing activities amounted to 78,400,000.00, significantly up from 17,000,000.00 in the prior period[24] - Cash outflow from financing activities totaled 103,754,320.53, compared to 39,356,135.12 previously[24] - The net cash flow from financing activities was -25,354,320.53, slightly worse than -22,356,135.12 in the last period[24] - The ending balance of cash and cash equivalents was 152,382,007.24, up from 150,098,941.99 at the end of the previous period[24] - The net increase in cash and cash equivalents for the quarter was 10,465,350.70, down from 31,870,420.96 in the previous quarter[24] Research and Development - R&D expenses decreased by ¥5,090,000, a reduction of 47.70% year-over-year[5] - Research and development expenses for Q3 2024 were ¥5,583,042.65, down from ¥10,675,860.37 in the same period last year[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 44,932[8] - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 23.81% of the shares[8] - The second-largest shareholder, Shaanxi International Trust Co., holds 3.84% of the shares[8] Legal and Regulatory Issues - The company has disclosed multiple legal proceedings related to asset management disputes, with updates provided on various dates throughout 2024[10] - The company has reported that some bank accounts have been frozen, with ongoing updates on the situation[12] - The company is actively communicating with the Shanghai Financial Court regarding the execution procedures related to a legal case[11] - The company is facing uncertainty regarding control changes, as a lawsuit has been filed against it, and the outcome is pending[16] Asset Management and Freezing Issues - The company’s assets have been frozen due to a loan dispute, with the equity of its wholly-owned subsidiary, Zhiyu Medical, frozen for an amount of CNY 50 million, lasting for 1,097 days[14] - The total frozen bank balance of the company and its subsidiaries is CNY 574,164.23, accounting for 0.13% of the latest audited net assets[14] - The company is actively negotiating with Zhejiang Zheshang Asset Management Co., Ltd. and Wenzhou Bank to resolve the asset and account freezing issues through extension, installment repayment, and financing replacement[14] - The company’s largest shareholder, Huayin Rifen, has sent a notice indicating that the Shanghai Pudong Development Bank Guangzhou Branch has become the sole trustee of a specific asset management plan[15] Investment Risks - The company emphasizes the importance of investors being aware of investment risks[11] Audit Status - The company has not undergone an audit for the third quarter report[24]

证券代码：002622 证券简称：皓宸医疗 公告编号：2024-039 《2024 年第三季度报告》详见公司指定信息披露媒体《中国证券报》、《上 海证券报》、《证券时报》及巨潮资讯网（www.cninfo.com.cn）2024 年 10 月 31 日公告。 皓宸医疗科技股份有限公司 二、备查文件 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届董事会第十三次会 议于2024年10月30日上午10:00在公司会议室以现场结合通讯表决方式召开。 召开本次会议的通知已于 2024 年 10 月 18 日以电话、电子邮件等方式通知了各 位董事，会议应参加表决董事 7 名，实际参加表决董事 7 名。此次会议的召集、 召开与表决程序符合《中华人民共和国公司法》和《公司章程》及相关法律、法 规的规定，合法有效。 一、审议通过《关于 2024 年第三季度报告的议案》 经与会董事认真审议并表决，通过了以下议案： 表决情况：同意 7 票，反对 0 票，弃权 0 票； 表决结果：通过。 1、《皓宸 ...

一、股票交易异常波动情况 皓宸医疗科技股份有限公司（以下称"公司"或"本公司"）股票（证券简 称：皓宸医疗，证券代码：002622）交易价格连续 3 个交易日（2024 年 10 月 22 日至 2024 年 10 月 24 日）收盘价格涨幅偏离值累计超过 20%，根据《深圳证券 交易所交易规则》的有关规定，属于股票交易异常波动的情形。 二、公司关注、核实情况的说明 针对公司股票异常波动，公司对有关事项进行了核查，并询问了公司第一大 股东，现将相关情况说明如下： 1、截至本公告日，公司前期披露的信息不存在需要更正、补充之处； 皓宸医疗科技股份有限公司 证券代码：002622 证券简称：皓宸医疗 公告编号：2024-038 股票交易异常波动公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 三、是否存在应披露而未披露的信息的声明 经公司董事会确认，除前述情况外，公司目前没有任何根据深交所《股票上 市规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、 意向、协议等；董事会也未获悉本公司有根据深交所《股票上市规则》等有关规 定应予以披露而未披露的、对 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2024-037 皓宸医疗科技股份有限公司关于第一大股东 执行事务合伙人收到《民事上诉状》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）于近日收到第一大股东广州 汇垠日丰投资合伙企业（有限合伙）（以下简称"汇垠日丰"）发来的《民事上诉状》。 北京首拓融汇投资有限公司（以下简称"北京首拓融汇"）因关于请求确认公司第 一大股东汇垠日丰执行事务合伙人广州汇垠澳丰股权投资基金管理有限公司（以 下简称"汇垠澳丰"）于 2023 年 8 月 4 日向北京首拓融汇发出的《关于解除<合作 协议>的函》无效一案，不服广州市南沙区人民法院出具的（2023）粤 0115 民初 10080 号民事判决，已向广州市中级人民法院提起上诉，现将相关事项公告如下： 一、本次诉讼的基本情况 公司分别于 2023 年 7 月 5 日、2023 年 8 月 9 日、2023 年 8 月 22 日在巨潮资 讯网披露了《关于公司控制权可能发生变更的提示性公告》（公告编号：2023-026）、 《 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2024-036 皓宸医疗科技股份有限公司关于第一大股东 执行事务合伙人收到《民事判决书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 因北京首拓融汇投资有限公司向广州市南沙区人民法院提出请求确认皓宸医 疗科技股份有限公司（以下简称"公司"）第一大股东广州汇垠日丰投资合伙企业 （有限合伙）执行事务合伙人广州汇垠澳丰股权投资基金管理有限公司于 2023 年 8 月 4 日向北京首拓融汇投资有限公司发出的《关于解除<合作协议>的函》无效一 案，公司收到公司第一大股东广州汇垠日丰投资合伙企业（有限合伙）发来的由广 州市南沙区人民法院出具的（2023）粤 0115 民初 10080 号《民事判决书》。现将相 关情况公告如下： 一、《民事判决书》主要内容 原告：北京首拓融汇投资有限公司 被告：广州汇垠澳丰股权投资基金管理有限公司 依据《中华人民共和国民法典》第五百零九条，《中华人民共和国民事诉讼法》 第六十七条，《最高人民法院关于适用<中华人民共和国民事诉讼法>的解释》第九 十条之规定，判决如下：驳回原告北 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2024-035 皓宸医疗科技股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股票交易异常波动情况 皓宸医疗科技股份有限公司（以下称"公司"或"本公司"）股票（证券简 称：皓宸医疗，证券代码：002622）交易价格连续 2 个交易日（2024 年 9 月 9 日、2024 年 9 月 10 日）收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交 易所交易规则》的有关规定，属于股票交易异常波动的情形。 二、公司关注、核实情况的说明 针对公司股票异常波动，公司对有关事项进行了核查，并询问了公司第一大 股东，现将相关情况说明如下： 经公司董事会确认，除前述情况外，公司目前没有任何根据深交所《股票上 市规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、 意向、协议等；董事会也未获悉本公司有根据深交所《股票上市规则》等有关规 定应予以披露而未披露的、对本公司股票及其衍生品种交易价格产生较大影响的 信息；公司前期披露的信息不存在需要更正、补充之处。 四、风险提示 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2024-034 皓宸医疗科技股份有限公司 关于公司及子公司部分银行账户被冻结的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 券交易所股票上市规则（2024 年修订）》第 9.8.1 条规定的其他风险警示情形。 | 序号 | 公司名称 | 开户行 | 账户性质 | 账户余额（元） | | | --- | --- | --- | --- | --- | --- | | 1 | 皓宸医疗科技股份有 | 交行北京上地支行 工行高新支行 | 一般户 | 3.77 | | | 2 | | 民生银行北京和平里支行 | | 492.82 | | | 3 | | | | 新增 | 231.64 | | 4 | 限公司 | 中行吉林市分行 | | | 3.09 | | 5 | | 农行汇春支行 | | | 5.64 | | 6 | | 民生银行吉林分行营业部 | | | 11.84 | | 7 | 吉林永大电气开关有 | 建行铁路支行 | 一般户 | 220,485.91 | | 截至目前，公司及子公司被冻结银行 ...

皓宸医疗科技股份有限公司 第五届监事会第十二次会议决议公告 证券代码：002622 证券简称：皓宸医疗 公告编号：2024-032 表决结果：通过。 经审核，监事会认为董事会编制和审核公司 2024 年半年度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 公司《2024 年半年度报告全文》具体内容详见公司指定信息披露网站巨潮 资讯网（www.cninfo.com.cn）2024 年 8 月 30 日公告；公司《2024 年半年度报 告摘要》具体内容详见公司指定信息披露媒体巨潮资讯网（www.cninfo.com.cn） 及《中国证券报》、《上海证券报》、《证券时报》2024 年 8 月 30 日公告。 二、备查文件 1、《皓宸医疗科技股份有限公司第五届监事会第十二次会议决议》。 特此公告。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届监事会第十二次会 议于 2024 年 8 月 19 日以电子邮件的形式发出 ...

| | 资金占用 | 占用方与上 | 上市公司 | 年 2024 | 年 月占 2024 1-6 | | 年 2024 | 1-6 | 年 2024 1-6 | | 年 2024 6 | 月 | 占用形 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 方名称 | 市公司的关 | 核算的会 | 期初占用 | 用累计发生金额 | | 月占用资金的 | | 月偿还累计 | | 30 日占用资 | | 成原因 | 占用性质 | | | | 联关系 | 计科目 | 资金余额 | （不含利息） | | 利息（如有） | | 发生金额 | | 金余额 | | | | | 控股股东、实际控制 | | | | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | | 非经营性占用 | | 小计 | | | | | | | | | | | | | | — | | 前控股股东、实际控 | | | | | ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥382,010,234.10, representing a 21.80% increase compared to ¥313,632,742.87 in the same period last year[11]. - The net profit attributable to shareholders of the listed company decreased by 92.74% to ¥553,485.18 from ¥7,620,553.84 in the previous year[11]. - The net cash flow from operating activities was ¥6,999,820.53, down 60.69% from ¥17,808,160.45 in the same period last year[11]. - Basic and diluted earnings per share both fell by 92.31% to ¥0.0007 from ¥0.0091 in the previous year[11]. - The total assets at the end of the reporting period were ¥1,552,258,203.13, a slight increase of 1.07% from ¥1,535,890,599.57 at the end of the previous year[11]. - The net assets attributable to shareholders of the listed company increased by 0.59% to ¥435,348,091.60 from ¥432,784,031.08 at the end of the previous year[11]. - The company reported a significant decrease in net profit after deducting non-recurring gains and losses, which was ¥169,061.90, down 97.08% from ¥5,789,833.83 in the previous year[11]. - The weighted average return on net assets was 0.13%, down from 1.32% in the previous year, indicating a decline in profitability[11]. - The company reported a total revenue of ¥376,015,931.87 from sales and services, an increase from ¥318,618,720.12 in the first half of 2023[97]. - The company reported a net profit distribution of 0.00, reflecting no dividends declared for the period[103]. Market and Business Operations - The company operates in the dental medical service sector and has established a dual business model of "dental medical services + industrial manufacturing" during the reporting period[15]. - The dental service market in China has grown from 92.3 billion yuan in 2015 to 261.07 billion yuan in 2023, with orthodontic products and services increasing from 22.09 billion yuan to 69.12 billion yuan[15]. - 德伦医疗 has 29 directly operated clinics covering over 35,000 square meters and has more than 400 dental chairs, making it one of the largest dental service providers in South China[16]. - The company is focused on expanding its market presence in Guangzhou and Foshan, leveraging its strong regional brand influence[15]. - The company aims to become the most trusted century-old dental brand, adhering to strict quality control measures[24]. - The company is actively pursuing compensation from a performance commitment party regarding the performance guarantee for Guangdong Delun Medical Group, with ongoing communication and potential arbitration measures[73]. Research and Development - Research and development expenses decreased by 43.90% to ¥3,605,476.51 from ¥6,427,417.24, reflecting a reduction in investment in innovation[25]. - The company holds over 40 utility model and invention patents in dental instruments, showcasing its commitment to technological advancement[23]. - The company is committed to digital transformation and innovation in the dental medical service sector, which is expected to enhance service quality and patient experience[15]. - The company has implemented a comprehensive training system for physicians to ensure a stable supply of skilled medical personnel[24]. Financial Management and Risks - The company is facing policy risks due to various regulatory policies supporting the oral healthcare industry, including the "Healthy Oral Action Plan (2019-2025)" aimed at improving oral health services[38]. - The company is addressing talent retention risks by focusing on talent reserve and team building to prevent talent loss in the competitive oral healthcare market[40]. - The company is actively communicating with creditors to explore feasible solutions for resolving asset and account freezes, including extensions and refinancing[42]. - The company is monitoring potential changes in control due to ongoing legal proceedings involving its major shareholders and related parties[43]. - The company plans to maintain strict risk management and scientific investment decisions while exploring new business models and growth opportunities[44]. Legal and Compliance - The company is involved in a significant lawsuit with Jin Haitang Asset Management Co., with a disputed amount of ¥362.30 million, which has resulted in an estimated liability[56]. - The company has a dispute with Beijing Shengyuan Tongchuang Technology Co., involving ¥76.38 million, with a ruling supporting the company's arbitration request[56]. - The company has ongoing litigation with Zhejiang Zheshang Asset Management Co., involving ¥135.25 million, currently in the execution phase[56]. - The company has not engaged in any external guarantees that violate regulations during the reporting period[53]. - The company has not reported any major litigation cases that meet the significant litigation standards[57]. Corporate Governance and Social Responsibility - The company has established a union to protect employee rights and regularly organizes training sessions for staff[50]. - The company actively engages in social responsibility initiatives, including energy conservation and environmental protection measures[50]. - The company has taken measures to support employment for disabled individuals by providing suitable job placements and necessary protections[50]. - The company has implemented strict controls on medical waste and wastewater disposal to enhance environmental protection[50]. Future Outlook - The company has set a future outlook with a revenue growth target of 10% for the next quarter[78]. - The company is expanding its market presence in Southeast Asia, aiming for a 15% market share by the end of the fiscal year[78]. - A strategic acquisition is planned, targeting a company with an estimated value of 50 million to enhance technological capabilities[78]. - The company provided a positive outlook for the second half of 2024, projecting a revenue growth of 20% to 600 million RMB[129].